Abstract:
Improving the balance of beneficial gut microbiota of an animal by providing a composition containing beta-casein, wherein at least 75% by weight of the beta-casein is a beta-casein variant that has a proline at position 67 of the beta-casein amino acid sequence.
Abstract:
Improving the cognitive function of an animal by providing a composition containing beta-casein, wherein at least 75% by weight of the beta-casein is a beta-casein variant that does not produce BCM-7 on digestion in the gut of the animal.
Abstract:
Improving the antioxidant capacity in an animal by increasing the level of glutathione in the blood or tissue of the animal comprising providing a composition containing beta- casein to the animal for consumption, where the beta-casein comprises at least 75% by weight of one or more beta-caseins not capable of producing beta-casomorphin-7 on enzymatic digestion. Uses include as an oxidant, for treating or preventing the symptoms of cancer, inflammation, kwashiorkor (protein deficiency), seizure, autism, Down's syndrome, chronic fatigue syndrome, Alzheimer's disease, Parkinson's disease, sickle cell anaemia, liver disease, cystic fibrosis, HIV, AIDS, infection, heart attack, stroke, and diabetes, avoiding or reducing the effects of aging, promoting the recovery of tissue following physical exercise, and promoting fertility.
Abstract:
A method for testing for the presence and quantification of A1-type beta-casein variants or A2-type beta-caseins, in milk and milk derived dairy products, using chymotrypsin digestion followed by LC-MS analysis to determining the concentrations of beta-casein digestion peptides and using the concentrations to calculate the amounts of A1-type beta-casein variants or A2-type beta-casein variants present.
Abstract:
Regulating the level of glucose in the blood of an animal comprising the consumption by the animal of a composition containing beta-casein, or providing the composition to the animal for consumption, where the beta-casein comprises at least 75% by weight beta-casein A2. Uses include managing the symptoms of hyperglycaemia and associated conditions including diabetes. The effect is both acute (post-exposure to the composition) and ongoing.
Abstract:
Preventing or reducing the symptoms of lactose intolerance in an animal comprising the consumption by the animal of a composition containing beta-casein, or providing the composition to the animal for consumption, where the beta-casein comprises at least 75% by weight beta-casein A2. The effect is both acute (post-exposure to the composition) and ongoing (future exposure to lactose).
Abstract:
The use of a composition for preventing or reducing the risk of inflammation of the bowel in an animal, wherein the composition contains beta-casein and wherein the beta-casein comprises at least 50% by weight beta-casein A2.
Abstract:
The use of milk for the preparation of a dairy product, wherein the milk contains at least 90% A2 beta-casein by weight of total beta-casein, and the dairy product has a viscosity at least 5% greater than the same dairy product prepared from milk containing less than 90% A2 beta-casein by weight of total beta-casein. Improved viscosity leads to improved foaming ability, frothing ability and/or mouthfeel of milk and dairy products.